Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Stopped early · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast.

Key facts

Study ID

NCT00082667

Run by

Vanderbilt-Ingram Cancer Center

People needed

1

Starts

2002-10-01

Expected to finish

2005-06-01

Last updated by the study team

2013-02-25

Who can join

Age: 35 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Meharry Medical College — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.